2024-520052-19-04RecruitingPhase 1/2
Research on two creams (Monobenzon / Imiquimod) together with the standard treatment for advanced or metastatic melanoma (ImMI).
Source: EU CTIS (euclinicaltrials.eu) · Last updated 13 Apr 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- First submitted
- 12 Jan 2026
- Start date
- 18 Sept 2026
- Lead sponsor
- Amsterdam UMC Stichting
- Diseases
- Melanoma
- EU CT number
- 2024-520052-19-04
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 18
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or metastatic melanoma who will get two creams (Monobenzon and Imiquimod) together with the standard treatment.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Advanced or metastatic melanoma
Read by machine on 9 Nov 2026.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amsterdam UMC Stichting | Amsterdam | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.